Novel compound heterozygous mutations in OCA2 gene associated with non-syndromic oculocutaneous albinism in a Chinese Han patient: a case report

Hairong Wang1, Yang Wan2, Yun Yang1,3, Hao Li1, Liangwei Mao1,4, Shuyang Gao5, Jingjing Xu6 and Jing Wang6

Abstract

Background: Oculocutaneous albinism (OCA) is a group of rare genetically heterogeneous disorders. The present study aimed to identify the genetic cause of a Chinese Han family with non-syndromic oculocutaneous albinism (OCA).

Case presentation: Here, we report an 11-month-old male proband from a Chinese Han non-consanguineous family, who presented with milky skin, yellow white hair, nystagmus, astigmatism, and hypermetropia. We performed the targeted next-generation sequencing (NGS) on the proband and identified two novel compound heterozygous variants (c.1865 T > C (p.Leu622Pro) and exons 17–21 deletion) in OCA2 gene associated with OCA type 2 (OCA2, OMIM 203200). Meanwhile, a previously reported heterozygous mutation (c.4805G > A) in MYO7 gene related with Usher syndrome type 1B was found. The online tools SIFT, PolyPhen-2, and Mutation Taster predicted variant c.1865 T > C was probably damaging. The residue p.Leu622 was in a highly conserved region among species by CLUSTALW. Three-dimensional homology model with I-TASSER indicated that p.Leu622Pro variant disturbed the formation of the α-helix, resulting in a random coil structure. The gross deletion (exons 17–21) in OCA2 gene has was not been reported previously. These two novel variants in OCA2 gene were inherited from each parent respectively, after verification by Sanger sequencing and quantitative PCR (qPCR) in the family.

Conclusions: This study indicates the two novel compound heterozygous mutations in OCA2 gene may be responsible for clinical manifestations of OCA2. It expands the mutation spectrum of OCA2 gene and is helpful to screen for large deletions with targeted NGS protocol in monogenic disease. It also assists the genetic counselling, carrier screening and personalized healthcare of the disease.

Keywords: Oculocutaneous albinism, OCA2, Non-syndromic, Gross deletion, Targeted NGS
The nsOCA can be broadly classified into several subtypes. At present, seven nsOCA genes have been described: *TYR* (OCA1A and OCA1B), *OCA2* (OCA2), *TYRP1* (OCA3), *SLC45A2* (OCA4), *SLC24A5* (OCA6), *LRMDA* (OCA7), and *MC1R* (Modifier of OCA2) [4]. The characteristics of the nsOCA differ among the different subtypes. OCA1A (OMIM 203100), is the most common and severe type, characterized by a complete loss of pigmentation, which caused by mutations in *TYR* gene. The other nsOCA are less severe, featured with some pigmentation over a lifetime. OCA2 (OMIM 203200) ranks as the second common nsOCA subtype [5, 6], and accounts for almost 30% of OCA cases worldwide [7]. The prevalence of OCA2 also differs widely among different populations. OCA2 patients present a mild to moderate pigmentation in hair, skin, and eyes. It is caused by mutations in *OCA2* gene (formerly called as P gene) which is located on chromosome 15q11.2-q12 spanning about 345 kb of genomic DNA in the region. The *OCA2* gene consists of 24 exons (23 coding) encoding an integral membrane protein which has 12 putative transmembrane domains and contains 838 amino acids [1, 8].

Clinical diagnosis of different OCA subtypes is always indistinguishable because of its overlapping and variable manifestations. The molecular and genetic analyses are helpful for accurate diagnosis, prognosis and genetic counseling. In this study, we described an 11-month-old patient diagnosed with OCA from a Chinese family.

**Case presentation**

An 11-month-old male proband is the first child of the non-consanguineous parents from China. He presented with creamy white skin, yellow white hair, accompanied with nystagmus, astigmatism, and hypermetropia. His father was phenotypically normal, his mother presented with yellow hair. We obtained approval from the BGI-Shenzhen ethics committee (No. BGI-IRB 17168). Written informed consent was obtained from the patient’s parents for participation in the present study before collecting peripheral blood. The parents of the proband declined publication of the clinical images.

**Genetic analysis**

In order to identify the etiology, targeted NGS was carried out on the proband with the 54 inherited eye disease genes panel, which includes four prevalent nsOCA genes: *TYR*, *OCA2*, *TYRP1*, and *SLC45A2*. (Additional file 1: Table S1). The total DNA extraction was performed using lymphocyte of peripheral blood by the QIAamp DNA extraction kit (Qiagen, Hilden, Germany), following the manufacturer’s instructions and recommendations. Genomic DNA was fragmented into 200 bp to 300 bp using an ultrasonoscope (Covaris S2, Massachusetts, USA). Then library construction was operated as previously published procedure [9]. The enriched library was sequenced using a HiSeq2500 Analyzers (Illumina, San Diego, CA, USA). The pipeline of bioinformatics analysis was performed to screen the mutations as a previous study [10]. The produced sequencing paired-end reads (90 bp) were aligned to the reference human genome (GRCh37/hg19) by Burrows Wheeler Aligner (bio-bwa.sourceforge.net). Single-nucleotide variant (SNV) and insertion and deletion (indel) were detected by SOAPsnp software (sourceforge.net/projects/soapsnp/) and the SAMtools (samtools.sourceforge.net) respectively. All SNVs and indels were filtered in the dbSNP, HapMap, 1 K human genome database and in-house database of 100 Chinese controls. Calling copy number variation (CNV) was performed according to a previous paper [11–13]. The deletion was identified by comparing the intra- and inter-sample normalized sequencing depth of each exon. Exons with a depth ratio 0.5 were considered to have heterozygous deletion, in contrast to the given sample. The sequence variants interpretation was conducted based on the guideline of the American College of Medical Genetics (ACMG).
We looked for candidate pathogenic variants in the proband by targeted NGS. The captured targeted region was 238,836 bp, and the coverage of the targeted region was 98.9%. The average sequencing depth of the panel was 204.43-fold, with 95.61% of the targeted bases covered a minimum of 30-fold. Three heterozygous variants were detected in the proband. The first was a missense mutation (c.1865 T > C, p.Leu622Pro) in exon 18 of OCA2 gene, the second was a gross deletion with exons 17–21 encompassed introns in OCA2 gene, and the third was a previously reported mutation (c.4805G > A, p.Arg1602Gln) in exon 35 of MYO7A gene with Usher Syndrome (US) [14], which clinically characterized with deafness and gradual vision loss.

To further evaluate the pathogenesis of the variant, three prediction programs PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/), and Mutation Taster (http://www.mutationtaster.org/) were used to predict the probability of variant c.1865 T > C in OCA2 gene. All prediction tools showed the variant was probably damaging. Multiple amino acid sequence alignment of OCA2 amino acid sequences with CLUSTALW (https://www.genome.jp/tools-bin/clustalw) showed that the missense variant (c.1865 T > C) was in a highly conserved region among species (Fig. 1). The three-dimensional (3D) models of native and mutant proteins were generated to predict the structure of proteins using the I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/). The result showed that the variant (c.1865 T > C) disturbed the formation of the α-helix, and formed a random coil structure (Fig. 2a, b), suggesting that it was a pathogenic mutation. Deletion of exons 17–21 affected the 3D structure of OCA2 protein, and leaded to a truncated and non-functional protein (Fig. 2c).

Confirmation of the novel mutation in the family
To ascertain three variants revealed by the targeted NGS, we conducted Sanger sequencing and quantitative PCR (qPCR) in the family with primers in Additional file 2: Table S2. The heterozygous variants c.1865 T > C (OCA2) and c.4805G > A (MYO7A) were both detected in the proband and his father (Fig. 3a, b). The quantity of exon 17–21 detected in the proband was consistent with his mother, almost half of his father and the control sample by qPCR (Fig. 4). The results demonstrated that the compound heterozygous variants in OCA2 gene of the proband were inherited from the parents respectively, and the proband was also a carrier of US.

Discussion
The OCA2 gene encodes integral membrane protein which belongs to the Na+/H+ antiporter family. The polypeptide includes 12 putative transmembrane α-helices domain, encoding an 838 amino acids with 110-KD. It acts as a precursor to melanin synthesis, controls the process of tyrosinase and tyrosinase-related protein [15], also maintains the pH of the melanosomes [16, 17]. The missense mutation

![Fig. 2 Modeling of the OCA2 protein. a p.Leu622. b p.Leu622Pro. c Structural representation of exons 17–21 deletion. Deleted residues are indicated in red and wild type residues are presented in blue.](image-url)
c.1865 T > C was previously unreported and predicted to impact the substitution of a proline for the leucine at residue 622 of the homeodomain. The p.Leu622 residue is located within the seventh transmembrane $\alpha$-helices domain, however, it changes into a random coil structure in p.Leu622Pro residue and results in the dysfunction of the OCA2 protein. The mutation p.Leu622Pro is functionally localized in Na-Sulphur-symporter domain which regulates the enzyme activity of tyrosinase by mediating intake of several molecules with the concomitant uptake of Na+ [18]. The deletion of exons 17–21 in OCA2 gene which spanning from 7 to 10 transmembrane $\alpha$-helices domains has not been reported before. It causes partial loss of Na-Sulphur-symporter domain, and is predicted to generate non-functional, truncated proteins. Several gross deletions encompassing this region were reported as the genetic cause of the OCA2, such as exons 3–20, exons 1–20, and exons 20–24 deletions in OCA2 gene [18, 19]. Taking these findings together, these two mutations may be responsible for clinical manifestations of OCA2.

The mutation types causing OCA2 are variable, including single SNV, indel and CNV, and gross deletions. So far, 177 relevant mutations have been reported in HGMD (Human Gene Mutation Database, professional 2019.1). Although the majority was nonsense/missense mutations, it was not able that 17 gross deletions in OCA2 gene have been described as genetic lesions for the OCA2 in HGMD. The most common deletion is a 2.7-kb deletion on exon 7 in patients of the African descent [20]. This study sheds light on the importance of routine genetic diagnostics with additional copy number analysis. Compared to Sanger sequencing, the targeted NGS is cost-effective to detect
monogenic disorders with various genetic lesions, including SNVs, indels, CNVs, or other factors in one step.

Conclusions
In summary, we identified two novel compound heterozygous mutations, one missense c.1865 T > C (p.Leu622-Pro) and one gross deletion (exons 17–21) in OCA2 gene in a Chinese Han family. This study enriches the mutation spectrum of OCA. The clinical phenotypes of OCA are always difficult to distinguish, gene diagnosis becomes a useful tool for the precise diagnosis, and assists the genetic counselling, carrier screening and personalized healthcare of the disease.

Additional files

Additional file 1: The list of 54 genes causing hereditary eye diseases. (DOCX 19 kb)

Additional file 2: Primer sequences for the Sanger sequencing and qPCR. (XLSX 9 kb)

Abbreviations
3D: Three-dimensional; CNV: Copy number variant; HPS: Hermansky–Pudlak Syndrome; Indel: Insertion/deletion; NGS: Next-generation sequencing; nsOCA: non-syndromic OCA; OCA: Oculocutaneous albinism; OCA1A: Oculocutaneous albinism type 1A; OCA2: Oculocutaneous albinism type 2; qPCR: quantitative PCR; SNV: Single nucleotide variant; US: Usher Syndrome

Acknowledgments
The authors thank the patient and his parents for taking part in this study.

Authors’ contributions
YW and JW provided clinical data and samples from patient and his family. HRW, and JW wrote the draft of the article. LWM, JJX carried out the molecular genetic experimental. HRW, YW, YY, HL, and SYG analyzed data. All authors have read and approved the final manuscript.

Funding
The authors declare that they did not receive any funding.

Availability of data and materials
The datasets reported in this study are deposited on the CNGB Nucleotide Sequence Archive (ICNSA: https://db.cnbg.org/cnsa; accession number CNP0000188). They are not publicly available due to the ethical principles of BGI-IRB but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was reviewed and approved by the Ethics Committee of BGI-Shenzhen (BGI-IRB17168). Written informed consent was obtained from the patient’s parents for participation of this study. The study was carried out following the Principles of the Declaration of Helsinki.

Consent for publication
Written informed consent of consent for publication of this case report was obtained for the patient’s parents.

Competing interests
The authors declare that they have no competing interests.

Author details
1Anhui Clinical Laboratories, BGI-Anhui, BGI-Shenzhen, Weisan Road, Fuyang 236000, China. 2Department of Obstetrics and Gynecology, Fuyang People’s Hospital, Fuyang 236000, China. 3Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 4College of Life Sciences, Hubei University, Wuhan 430062, China. 5BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China. 6Prenatal diagnosis center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230071, China.

Received: 5 February 2019 Accepted: 19 June 2019
Published online: 25 July 2019

References
1. Gronskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43.
2. Khordadpoor-Deilamani F, Akbari MT, Karimipoor M, Javadi G. Sequence analysis of tyrosinase gene in ocular and oculocutaneous albinism patients: introducing three novel mutations. Mol Vis. 2015;21:730–5.
3. Wang Y, Wang Z, Chen M, Fan N, Yang J, Liu L, et al. Mutational analysis of the TYR and OCA2 genes in four Chinese families with Oculocutaneous albinism. PLoS One. 2015;10:e0125651.
4. Gul H, Ali MZ, Khan E, Zubair M, Badar M, Khan S, et al. Ophthalmologic analysis of Pakistani patients with nonsyndromic oculocutaneous albinism through whole exome sequencing. J Pak Med Assoc. 2017;67:790–2.
5. Laneaux E, Plaisant C, Michaud V, Pennannen P, Trimouille A, Gaston L, et al. Molecular characterization of a series of 990 index patients with albinism. Pigment Cell Melanoma Res. 2018;31:466–74.
6. Zhong Z, Gu L, Zheng X, Ma N, Wu Z, Duan J, et al. Comprehensive analysis of spectral distribution of a large cohort of Chinese patients with non-syndromic Oculocutaneous albinism facilitates genetic diagnosis. Pigment Cell Melanoma Res. 2019. https://doi.org/10.1111/pcmr.12790.
7. Rooyck C, Motice-Picard F, Lasseaux E, Caillé D, Dollfus H, Defoort-Dhellerinne S, et al. High resolution mapping of OCA2 intragenic rearrangements and identification of a founder effect associated with a deletion in polish albino patients. Hum Genet. 2011;129:199–8.
8. Lee ST, Nicholls RD, Jong MT, Fukai K, Spritz RA. Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics. 1995;26:334–63.
9. Wei X, Ju X, Yi X, Zhu Q, Qu N, Liu T, et al. Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One. 2011;6:e29500.
10. Liu Y, Wei X, Kong X, Guo X, Sun Y, Man J, et al. Targeted next-generation sequencing for clinical diagnosis of 561 Mendelian diseases. PLoS One. 2015;10:e0133636.
11. Yang Y, Mao B, Wang L, Mao L, Zhou A, Cao J, et al. Targeted next-generation sequencing reveals a novel intragenic deletion of the LAMA2 gene in a patient with congenital muscular dystrophy. Mol Med Rep. 2015;11:3687–93.
12. Goossens D, Moens LN, Nelis E, Lenaerts AS, Glassée W, Kalbe A, et al. Simultaneous mutation and copy number variation (CNV) detection by multiplex PCR-based GS-FLX sequencing. Hum Mutat. 2009;30:472–6.
13. Kumps C, Van Roy N, Heymann L, Goossens D, Del-Favero J, Noquera R, et al. Multiplex amplicon quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma. BMC Genomics. 2010;11:298.
14. Chen M, Bittner-Glindzicz M, Luxon L. The changing face of usher syndrome: clinical implications. Int J Audiol. 2007;46:82–93.
15. Chen K, Manga P, Orlov SJ. Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell. 2002;13:1953–64.
16. Ni-Komatsu L, Orlow SJ. Heterologous expression of tyrosinase recapitulates the enzymatic and biosynthetic activities in oculocutaneous albinism type 2: effects of altering intracellular pH and pink-eyed dilution gene expression. Exp Eye Res. 2006;82(2):519–28.
17. Bellomo NW, Escobar IE, Lefkowitz AJ, Marks MS, Oancea E. An intracellular anion channel critical for pigmentation. Elife. 2014;3:e04543.
18. Shahzad M, Yousaf S, Waryah YM, Gul H, Kausar T, Tarqi N, et al. Molecular outcomes, clinical consequences, and genetic diagnosis of Oculocutaneous albinism in Pakistani population. Sci Rep. 2017;7:44185.
19. Rooryck C, Morice-Picard F, Elcioglu NH, Lacombe D, Taieb A, Arveiler B. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res. 2008; 21:583–7.

20. Stevens G, Ramsay M, Jenkins T. Oculocutaneous albinism (OCA2) in sub-Saharan Africa: distribution of the common 2.7-kb P gene deletion mutation. Hum Genet. 1997;99:523–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.